Related Experiment Videos
Hypoglycemic coma associated with subcutaneous insulin infusion by portable pump
Diabetes Care
|May 1, 1981
Summary
Continuous subcutaneous insulin infusion (CSII) can lead to severe hypoglycemia, even in compliant patients. Close medical supervision is crucial to prevent this potentially fatal complication of insulin pump therapy.
Area of Science:
- Endocrinology
- Metabolic Disorders
- Diabetes Management
Background:
- Continuous subcutaneous insulin infusion (CSII) is a common treatment for insulin-dependent diabetes.
- The incidence of hypoglycemia with CSII is generally reported as low.
Observation:
- A case of severe hypoglycemia coma occurred in a highly compliant patient using a portable insulin pump.
- Contributing factors included tight glycemic control, delayed recognition of symptoms, and prolonged hypoglycemia due to the open-loop system.
Findings:
- Hypoglycemia remains a significant complication of CSII therapy.
- Even well-controlled and intelligent patients are at risk.
Implications:
- CSII therapy requires careful patient selection and physician experience.
- Constant patient supervision is essential to mitigate the risks of severe hypoglycemia.
- This complication highlights the need for vigilance in managing diabetes with insulin pumps.